Literature DB >> 17194517

Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.

Ellen G Duysen1, Bin Li, Sultan Darvesh, Oksana Lockridge.   

Abstract

Butyrylcholinesterase (EC 3.1.1.8 BChE) is present in all human and mouse tissues, and is more abundant than acetylcholinesterase (EC 3.1.1.7 AChE) in all tissues except brain. People who have no BChE activity due to a genetic variation are healthy. This has led to the hypothesis that BChE has no physiological function. We tested this hypothesis by challenging BChE and AChE knockout mice, as well as wild-type mice, with the AChE specific inhibitors, (--)-huperzine A and donepezil, and with serine hydrolase inhibitors, echothiophate and chlorpyrifos oxon. (--)-Huperzine A and donepezil caused mortality and significant toxicity in the BChE-/- animals. The BChE heterozygote (BCHE+/-) mice with approximately one-half the BChE activity of the BChE wild type (BChE+/+) exhibited intermediate toxic symptoms, and survived a longer period. The BChE+/+ animals displayed comparatively minor toxic symptoms and recovered by 24h post-dosing. Plasma AChE activity was inhibited to the same extent in BChE-/-, +/-, and +/+ mice, whereas BChE activity was not inhibited. This indicated that the protective effect of BChE was not due to scavenging (--)-huperzine A. AChE-/- mice were unaffected by (--)-huperzine A and donepezil, demonstrating the specificity of these inhibitors for AChE. AChE-/- mice treated with chlorpyrifos oxon lost all BChE activity, had severe cholinergic symptoms and died of convulsions. This showed that BChE activity was essential for survival of AChE-/- mice. In conclusion, we propose that the protective effect of BChE is explained by hydrolysis of excess acetylcholine in physiologically relevant regions such as diaphragm, cardiac muscle, and brain. Thus, BChE has a function in neurotransmission. People with BChE deficiency are expected to be intolerant of standard doses of the anti-Alzheimer's drugs, (--)-huperzine A and donepezil.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17194517     DOI: 10.1016/j.tox.2006.11.069

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  22 in total

Review 1.  Cocaine hydrolase gene therapy for cocaine abuse.

Authors:  Stephen Brimijoin; Yang Gao
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

2.  Direct correlation between molecular dynamics and enzymatic stability: a comparative neutron scattering study of native human butyrylcholinesterase and its "aged" soman conjugate.

Authors:  F Gabel; P Masson; M-T Froment; B P Doctor; A Saxena; I Silman; G Zaccai; M Weik
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

Review 3.  Neurochemistry of the Anterior Thalamic Nuclei.

Authors:  Witold Żakowski
Journal:  Mol Neurobiol       Date:  2016-08-30       Impact factor: 5.590

4.  Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors.

Authors:  Sugunadevi Sakkiah; Keun Woo Lee
Journal:  Acta Pharmacol Sin       Date:  2012-06-11       Impact factor: 6.150

Review 5.  Reassessment of the role of the central cholinergic system.

Authors:  Anna Hrabovska; Eric Krejci
Journal:  J Mol Neurosci       Date:  2013-11-10       Impact factor: 3.444

Review 6.  Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior.

Authors:  Patrick Masson; Oksana Lockridge
Journal:  Arch Biochem Biophys       Date:  2009-12-11       Impact factor: 4.013

7.  Characterization of butyrylcholinesterase from porcine milk.

Authors:  Ashima Saxena; Tatyana Belinskaya; Lawrence M Schopfer; Oksana Lockridge
Journal:  Arch Biochem Biophys       Date:  2018-06-15       Impact factor: 4.013

8.  Intrathecal delivery of fluorescent labeled butyrylcholinesterase to the brains of butyrylcholinesterase knock-out mice: visualization and quantification of enzyme distribution in the brain.

Authors:  Noel D Johnson; Ellen G Duysen; Oksana Lockridge
Journal:  Neurotoxicology       Date:  2009-03-20       Impact factor: 4.294

9.  Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis.

Authors:  Mohammad A Kamal; Xianqin Qu; Qian-Sheng Yu; David Tweedie; Harold W Holloway; Yazhou Li; Yi Tan; Nigel H Greig
Journal:  J Neural Transm (Vienna)       Date:  2008-01-31       Impact factor: 3.575

10.  Influence of differential expression of acetylcholinesterase in brain and muscle on respiration.

Authors:  Eliane Boudinot; Véronique Bernard; Shelley Camp; Palmer Taylor; Jean Champagnat; Eric Krejci; Arthur S Foutz
Journal:  Respir Physiol Neurobiol       Date:  2008-10-11       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.